Modern technology of radiation therapy: IMRT, VMAT using simultanting integrated boost (SIB) in the complex treatment of squamous cell carcinoma of the anal canal


如何引用文章

全文:

详细

Increased survival of patients with squamous cell carcinoma of the anal canal due to improved technical equipment radiotherapy separated to oncology clinics. Creating conditions accurately summarizing the planned dose decrease absorption substituted doses to critical structures, reducing unscheduled interruptions in the course of chemoradiotherapy with modern technology conformal radiotherapy (3D CRT, IMRT, VMAT).Radiotherapy with intensity modulated (IMRT) and intensity modulation arches VMAT («Rapid Arc») held respectively at 9 and 5 paintion of squamous cell carcinoma of the anal canal. At the same time the primary tumor and lymph node involvement is further subjected to daily exposure Simula mutant integrated boost (SIB).Application of these technologies allowed: 1) get high oncological result (complete tumor regression in all patients); 2) to reduce the radiation dose to critical organs (small intestine - the average minimum dose, Dose Mean) 34,0 Gy (with IMRT); 37,2 Gy (with 3D CRT); bladder - (Dose Mean) 24,2 Gy (with IMRT); 26,2 Gy (with 3D CRT), respectively; 3) reduce the frequency and intensity of acute radialdamage critical organs: toxic heavy early mucositis (III-IV degree) from the rectum and bladder were observed in any observation. Early proctitis degree I was diagnosed in 4 (28,6% of patients), proctitis Grade II in 5 (35,7%) patients. Early cystitis degree I was diagnosed in 3 (21,4%) patients, cystitis II degree in 6 (42,8%) patients; catarrhal mucosal epithelium of the female genital organs occurred in 8 (57,1%) patients; 1 month after the end of radiotherapy proctitis degree I recorded in 5 (35,7%) and cystitis I degree in 4 (28,6%) patients; 4) reduce the number of patients with forced interruptions termoradiohimioterapii: only 6 patients (42,8%) due to hematological toxicity grade I-II, II degree cystitis made a short break in treatment, the duration of which was 5-8 days; 5) Use simultanting integrated boost (SIB) has led to a reduction in duration of the full course termoradiohimioterapii 7 working days compared to traditional small fraction 3D CRT radiation therapy; 6) the use of space modulated radiotherapy arches (VMAT - «Rapid Arc») has allowed to reduce the time of a session of radiotherapy with IMRT compared with 20-30 minutes to 3-5 minutes.Volume modulated radiation therapy technology using SIB reduce the time the patient’s treatment, the number of complications and achieve complete tumor regression.

作者简介

S Tkachev

ФГБУ Российский онкологический научный центр им. Н.Н.Блохина РАМН, Москва

д-р мед. наук, проф., зав. отд. радиационной онкологии

V Glebovskaya

ФГБУ Российский онкологический научный центр им. Н.Н.Блохина РАМН, Москва

канд. мед. наук, науч. сотр. радиологического отд-ния НИИ клинической онкологии

A Rasulov

ФГБУ Российский онкологический научный центр им. Н.Н.Блохина РАМН, Москва

д-р мед. наук, зав. хирургическим отд-нием №3 (проктологическим) НИИ клинической онкологии

V Tsariuk

ФГБУ Российский онкологический научный центр им. Н.Н.Блохина РАМН, Москва

д-р мед. наук, вед. науч. сотр. отд-ния хирургического №3 (проктологического) НИИ клинической онкологии

V Aliev

ФГБУ Российский онкологический научный центр им. Н.Н.Блохина РАМН, Москва

канд. мед. наук, ст. науч. сотр. отд-ния хирургического №3 (проктологического) НИИ клинической онкологии

V Vodyanik

ФГБУ Российский онкологический научный центр им. Н.Н.Блохина РАМН, Москва

вед. инженер отд-ния лучевой топометрии и клинической дозиметрии НИИ клинической онкологии

参考

  1. Mitchell M.P, Abboud M, Eng C et al. Intensity - modulated radiation therapy with concurrent chemotherapy for anal cancer: outcomes and toxicity. Departments of Radiation Oncology Gastrointestinal Medical Oncology Radiation Physics. UT MD Anderson Cancer Center. Houston, TX. Am J Clin Oncol 2013.
  2. Chuong M.D, Freilich J.M, Hoffe S.E et al. Intensity - modulated radiation therapy vs. 3D conformal radiation therapy for squamous cell carcinoma of the anal canal. Department of Radiation Oncology. Gastrointest Cancer Res 2013; 6 (2): 39-45.
  3. Saarilahti K, Arponen P, Vaalavirta L et al. The effect of intensity - modulated radiotherapy and high dose rate brachytherapy on acute and late radiotherapy - related adverse events following chemoradiotherapy of anal cancer. Radiother Oncol 2008; 87: 383-90.
  4. Dubois J, Vieillot S, Moscardo C.L et al. A planning study to compare plans using volumetric modulated arc therapy or intensity - modulated radiation therapy for the treatment of anal cancer. Crlc Val D’aurelle, Montpellier, France. J Radiat Oncol Biol Physics 2009; 75 (3).
  5. Cox J.D, Stetz J, Pajak T.F. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995; 31: 1341-6.
  6. UKCCCR Anal Cancer Working Party. Epidermoid Anal Cancer: Results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil and Mitomycin. Lancet 1996; 348: 1049-54.
  7. Bilimoria K.Y, Bentrem D.J, Rock C.E et al. Outcomes and prognostic factors for squamous - cell carcinoma of the anal canal. Analysis of patients from the National Cancer Data Base. Dis Colon Rectum 2009; 52: 624-31.
  8. Engstrom P.F, Amoletti J.P, Benson A.B et al. NCCN Practice Guidelines: Anal Cancer. Vers. 2.2009; www.nccn.org/professionals/physician
  9. Glynne-Jones R, Northover J, Cervantes A. ESMO Guidelines Working Group. Anal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow - up. Ann Oncol 2010; 21 (Suppl. 5): v87-92.
  10. Nigro N.D, Seydel H.G, Considine B. Jr et al. Combined radiotherapy and chemotherapy for squamous cell carcinoma of the anal canal. Cancer 1983; 51: 1826-9.
  11. Leichman L, Nigro N, Vaitkevicius V.K et al. Cancer of the anal canal: Model for preoperative adjuvant combined modality therapy. Am J Med 1985; 78: 211-5.
  12. Bartelink H, Roelofsen F, Eschwege F et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: Results of a Phase III randomized trial of the European Organization for Research and Treatment of Cancer radiotherapy and gastrointestinal cooperative groups. J Clin Oncol 1997; 15: 2040-9.
  13. Flam M, John M, Pajak T.F et al. Role of mitomycin in combination with fluorouracil and radiotherapy and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: Results of a phase III randomized Intergroup Study. J Clin Oncol 1996; 14: 2527-39.
  14. Martenson J.A, Lipsitz S.R, Leftkopoulou M et al. Results of combined modality therapy for patients with anal cancer (E-7283): An Eastern Cooperative Oncology Group study. Cancer 1995; 76: 1731-6.
  15. Borzomati D, Valeri S, Ripetti V et al. Persisting anal ulcer after radiotherapy for anal cancer: recurrence of disease or late radiation - related complication? Hepatogastroenterol 2005; 52: 780-4.
  16. Tanum G, Tveit K.M, Karlsen K.O. Chemoradiotherapy of anal carcinoma: Tumour response and acute toxicity. Oncology 1993; 50: 14-7.
  17. Schwarz J.K, Siegel B.A, Dehdashti F et al. Tumor response and survival predicted by post - therapy FDG-PET/CT in anal cancer. Int J Radiat Oncol Biol Phys 2008; 71: 180-6.
  18. Ajani J.A, Winter K.A, Gunderson L.L et al. Prognostic factors derived from a prospective database dictate clinical biology of anal cancer: The intergroup trial (RTOG 98-11). Cancer 2010.
  19. Ajani J.A, Winter K.A, Gunderson L.L et al. US Intergroup Anal Carcinoma Trial: Tumor diameter predicts for colostomy. J Clin Oncol 2009; 27: 1116-21.
  20. James R, Wan S, Glynne-Jones R et al. A randomised trial of chemoradiation using Mitomycin or cisplatin, with or without maintenance cisplatin/5FU in squamous cell carcinoma of the anus. J Clin Oncol 2009; 2 (2) 27: 18S; 797s. Abstr. LBA-4009.
  21. Ajani J.A, Winter K.A, Gunderson L.L et al. Fluorouracil, mitomycin and radiotherapy vs. fluorouracil, cisplatin and radiotherapy for carcinoma of the anal canal: A randomized controlled trial. JAMA 2008; 199: 1914-21.
  22. Cummings B.J, Brierley J.D. Anal canal. In: C.Perez, L.Brady, E.Halperin et al. (ed.). Principles and Practice of Radiation Oncology. 4th ed. Lippincott Williams & Wilkins: Philadelphia 2004; p. 1630-48.
  23. Matthews J. Early anal canal carcinoma - the Trans-Tasman Radiation Oncology Group (TROG) experience in TROG 99.02 study. Austral Radiol 2005; 49: A3.
  24. Salama J.K, Mell L.K, Schomas D.A et al. Concurrent chemotherapy and intensity - modulated radiation therapy for anal canal cancer patients: A multicenter experience. J Clin Oncol 2007; 25: 4581-6.
  25. Myerson R.J, Garofalo M.C, El Naqa I et al. Elective clinical target volumes for conformal therapy in anorectal cancer: A radiation therapy oncology group consensus panel contouring atlas. Int J Radiat Oncol Biol Phys 2009; 74: 824-30.
  26. Kachnic L, Winter K, Myerson R et al. RTOG 0529: A phase II evaluation of dose painted IMRT in combination with 5-fluorouracil and Mitomycin C for reduction of acute morbidity in carcinoma of the anal canal. Int J Radiat Oncol Biol Phys 2009; 75 (3). Suppl. Proc ASTRO S5. Abstr. 10.

版权所有 © Consilium Medicum, 2014

Creative Commons License
此作品已接受知识共享署名-非商业性使用 4.0国际许可协议的许可。
 


##common.cookie##